Skip Navigation LinksHome > August 2013 - Volume 35 - Issue 6 > Successful Treatment of Diffuse Large B-Cell Lymphoma in a P...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e3182804d59
Clinical and Laboratory Observations

Successful Treatment of Diffuse Large B-Cell Lymphoma in a Patient With Ataxia Telangiectasia Using Rituximab

Machida, Shizuka MD; Tomizawa, Daisuke MD, PhD; Tamaichi, Hiroyuki MD; Okawa, Teppei MD; Endo, Akifumi MD; Imai, Kohsuke MD, PhD; Nagasawa, Masayuki MD, PhD; Morio, Tomohiro MD, PhD; Mizutani, Shuki MD, PhD; Takagi, Masatoshi MD, PhD

Collapse Box


Ataxia-telangiectasia (A-T) is an autosomal recessive disorder characterized by cerebellar ataxia, telangiectasia, immune defect, and predisposition to leukemia/lymphoma. Because of their hypersensitivity to DNA-damaging agents, patients with A-T may require special consideration. However, an optimal strategy for these patients has not been established. Here, we describe an A-T female with diffuse large B-cell lymphoma successfully treated with rituximab combined with reduced-dose chemotherapy. Given the high incidence of hematopoietic malignancies in patients with A-T, and the hypersensitivity of these patients to DNA-damaging agents, we discuss whether a reduced-dose chemotherapy with a molecular targeting agent may be of merit.

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.